Informed Consent Parent | Informed Consent Legal Guardian | Informed Consent
Item
parent or legal guardian is able to provide written informed consent and patient is able to provide written assent if appropriate.
boolean
C0021430 (UMLS CUI [1,1])
C0030551 (UMLS CUI [1,2])
C0021430 (UMLS CUI [2,1])
C0023226 (UMLS CUI [2,2])
C0021430 (UMLS CUI [3])
Adolescent | Age
Item
male and female adolescents aged 12 to 16 years at the time of enrollment.
boolean
C0205653 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Juvenile arthritis | Oligoarticular Arthritis | Polyarthritis Rheumatoid factor positive | Polyarthritis Rheumatoid factor negative | Arthritis, Psoriatic | Enthesitis-Related Arthritis | Undifferentiated Juvenile Idiopathic Arthritis | Systemic onset juvenile chronic arthritis
Item
diagnosed with jia, including all the ilar jia subtypes: oligoarthritis, polyarthritis (both rf+ and rf-), psoriatic arthritis, enthesitis-related arthritis,undifferentiated arthritis, and systemic arthritis.
boolean
C3495559 (UMLS CUI [1])
C3892044 (UMLS CUI [2])
C0162323 (UMLS CUI [3,1])
C0151379 (UMLS CUI [3,2])
C0162323 (UMLS CUI [4,1])
C0427391 (UMLS CUI [4,2])
C0003872 (UMLS CUI [5])
C3495919 (UMLS CUI [6])
C3897245 (UMLS CUI [7])
C1384600 (UMLS CUI [8])
Vimovo
Item
based upon investigator judgment, it is determined appropriate for the patient to undergo 6 months of continuous treatment with vimovo.
boolean
C2918032 (UMLS CUI [1])
Body Weight | Body mass index percentile per age
Item
body weight >31 kg (68.2 lbs) and within the 5th to 95th percentile of body mass index for age.
boolean
C0005910 (UMLS CUI [1])
C3838397 (UMLS CUI [2])
Systemic onset juvenile chronic arthritis | Feature Systemic | Fever | Exanthema | Other Coding | Serositis | Lymphadenopathy | Macrophage Activation Syndrome
Item
in systemic jia patients, presence of systemic features (ie, fever, rheumatoid rash, serositis, lymphadenopathy, macrophage activation syndrome) within 6 months prior to start of study drug.
boolean
C1384600 (UMLS CUI [1])
C2348519 (UMLS CUI [2,1])
C0205373 (UMLS CUI [2,2])
C0015967 (UMLS CUI [3])
C0015230 (UMLS CUI [4])
C3846158 (UMLS CUI [5])
C0036749 (UMLS CUI [6])
C0497156 (UMLS CUI [7])
C1096155 (UMLS CUI [8])
Naproxen U/day
Item
currently taking (ie, within 4 weeks prior to start of drug) naproxen >20 mg/kg/day or >1000 mg total daily dose.
boolean
C0027396 (UMLS CUI [1,1])
C0456683 (UMLS CUI [1,2])
Hemoglobin measurement
Item
hemoglobin ≤8.5 g/dl.
boolean
C0518015 (UMLS CUI [1])
Cardiovascular Disease | Cerebrovascular Disorder
Item
individuals who have cardiovascular or cerebrovascular disease, based on history or risk factors.
boolean
C0007222 (UMLS CUI [1])
C0007820 (UMLS CUI [2])
Liver diseases | Kidney Diseases | Lung diseases | Disorder of eye | Nervous system disorder | Other medical condition At risk Patient | Medical History | History of prior surgery | Physical Examination | Laboratory examination
Item
any significant hepatic, renal, pulmonary, ophthalmologic, neurologic, or any other medical conditions indicated by medical/surgical history, physical, or laboratory examination that might put the patient at greater risk during the study.
boolean
C0023895 (UMLS CUI [1])
C0022658 (UMLS CUI [2])
C0024115 (UMLS CUI [3])
C0015397 (UMLS CUI [4])
C0027765 (UMLS CUI [5])
C3843040 (UMLS CUI [6,1])
C1444641 (UMLS CUI [6,2])
C0030705 (UMLS CUI [6,3])
C0262926 (UMLS CUI [7])
C0744961 (UMLS CUI [8])
C0031809 (UMLS CUI [9])
C0260877 (UMLS CUI [10])